Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel for primary prevention in subclinical coronary atherosclerosis
KCT0008319Phase 4Recruiting
- Sponsor
- Samjin Pharmaceutical, Yuhan, Ildong pharmaceutical, Chong Kun Dang , Dong-A ST, Hanmi Pharm, Daewoong
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of clopidogrel in coronary arteriosclerosis, sponsored by Samjin Pharmaceutical, Yuhan, Ildong pharmaceutical, Chong Kun Dang , Dong-A ST, Hanmi Pharm, Daewoong. Started Mar 2023; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on KCT0008319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008319.